Day 70 #ScienceAIBench: antibody polyreactivity. GPT 5.5 leads (peak 0.152 Ovalbumin). Predicting nonspecific antibody binding stays a near-zero blind spot for every model. #DrugDiscovery #InsilicoBench
July 12, 2026 at 2:38 PM
Day 70 #ScienceAIBench: antibody polyreactivity. GPT 5.5 leads (peak 0.152 Ovalbumin). Predicting nonspecific antibody binding stays a near-zero blind spot for every model. #DrugDiscovery #InsilicoBench
Day 71 #ScienceAIBench: Dopamine receptors D1-D4. GPT 5.5 wins 3/4 subtypes, peak Spearman 0.627 on D2. D4 hardest (max 0.228). Frontier captures dopamine SAR partly — subtype gaps remain. #DrugDiscovery #InsilicoBench
July 13, 2026 at 1:05 PM
Day 71 #ScienceAIBench: Dopamine receptors D1-D4. GPT 5.5 wins 3/4 subtypes, peak Spearman 0.627 on D2. D4 hardest (max 0.228). Frontier captures dopamine SAR partly — subtype gaps remain. #DrugDiscovery #InsilicoBench
Day 69 #ScienceAIBench: Lipophilicity & Solubility (ADMET). GPT 5.5 wins 4/4, peaking 0.925 on LogP. Kinetic Solubility hardest (max 0.314). LogP nearly solved; aqueous solubility still meaningfully harder. #DrugDiscovery #InsilicoBench
July 11, 2026 at 5:57 PM
Day 69 #ScienceAIBench: Lipophilicity & Solubility (ADMET). GPT 5.5 wins 4/4, peaking 0.925 on LogP. Kinetic Solubility hardest (max 0.314). LogP nearly solved; aqueous solubility still meaningfully harder. #DrugDiscovery #InsilicoBench
Day 68 of #ScienceAIBench: subtype selectivity on opioid receptors (Delta/Kappa/Mu). GPT 5.5 wins all 3, peaking 0.639 on OPRD1; Gemini 3.1 Pro 2nd. Mu (OPRM1) stays hardest - no model clears 0.330. Grok 4.3 trails, dips negative.\n\n#DrugDiscovery #InsilicoBench
July 10, 2026 at 3:48 PM
Day 68 of #ScienceAIBench: subtype selectivity on opioid receptors (Delta/Kappa/Mu). GPT 5.5 wins all 3, peaking 0.639 on OPRD1; Gemini 3.1 Pro 2nd. Mu (OPRM1) stays hardest - no model clears 0.330. Grok 4.3 trails, dips negative.\n\n#DrugDiscovery #InsilicoBench